76 related articles for article (PubMed ID: 31301282)
1. Quick assessment of cell-free DNA in seminal fluid and fragment size for early non-invasive prostate cancer diagnosis.
Ponti G; Maccaferri M; Manfredini M; Micali S; Torricelli F; Milandri R; Del Prete C; Ciarrocchi A; Ruini C; Benassi L; Bettelli S; Kaleci S; Ozben T; Tomasi A
Clin Chim Acta; 2019 Oct; 497():76-80. PubMed ID: 31301282
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients.
Jarmuzek P; Wawrzyniak-Gramacka E; Morawin B; Tylutka A; Zembron-Lacny A
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673808
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
Liu SC
World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
[TBL] [Abstract][Full Text] [Related]
4. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies.
Martin-Alonso C; Tabrizi S; Xiong K; Blewett T; Sridhar S; Crnjac A; Patel S; An Z; Bekdemir A; Shea D; Wang ST; Rodriguez-Aponte S; Naranjo CA; Rhoades J; Kirkpatrick JD; Fleming HE; Amini AP; Golub TR; Love JC; Bhatia SN; Adalsteinsson VA
Science; 2024 Jan; 383(6680):eadf2341. PubMed ID: 38236959
[TBL] [Abstract][Full Text] [Related]
5. Blood-Based DNA Methylation Analysis by Multiplexed OBBPA-ddPCR to Verify Indications for Prostate Biopsies in Suspected Prostate Cancer Patients.
Friedemann M; Jandeck C; Tautz L; Gutewort K; von Rein L; Sukocheva O; Fuessel S; Menschikowski M
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611002
[TBL] [Abstract][Full Text] [Related]
6. Isolation and Characterization of Cell-Free DNA from Cerebral Organoids.
Silver BB; Brooks A; Gerrish K; Tokar EJ
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791569
[TBL] [Abstract][Full Text] [Related]
7. Ampholytic ion-exchange magnetic beads: a promising tool for selecting short fragments in circulating cell-free DNA analysis.
He G; Wang W; Zhou Y; Zhao G; Liao J
Front Oncol; 2024; 14():1397680. PubMed ID: 38779084
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Plasma Circulating Cell Free DNA Concentration and Integrity in Patients with Prostate Cancer in Jamaica: A Preliminary Study.
Condappa A; McGrowder D; Aiken W; McLaughlin W; Gossell-Williams M
Diseases; 2020 Sep; 8(3):. PubMed ID: 32906694
[TBL] [Abstract][Full Text] [Related]
9. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
[TBL] [Abstract][Full Text] [Related]
10. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
Vandekerkhove G; Lavoie JM; Annala M; Murtha AJ; Sundahl N; Walz S; Sano T; Taavitsainen S; Ritch E; Fazli L; Hurtado-Coll A; Wang G; Nykter M; Black PC; Todenhöfer T; Ost P; Gibb EA; Chi KN; Eigl BJ; Wyatt AW
Nat Commun; 2021 Jan; 12(1):184. PubMed ID: 33420073
[TBL] [Abstract][Full Text] [Related]
11. Glutathione-S-Transferase
Ye J; Wu M; He L; Chen P; Liu H; Yang H
Int J Endocrinol; 2023; 2023():7279243. PubMed ID: 36747996
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance.
Stejskal P; Goodarzi H; Srovnal J; Hajdúch M; van 't Veer LJ; Magbanua MJM
Mol Cancer; 2023 Jan; 22(1):15. PubMed ID: 36681803
[TBL] [Abstract][Full Text] [Related]
13. Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer.
Rzhevskiy AS; Kapitannikova AY; Butnaru DV; Shpot EV; Joosse SA; Zvyagin AV; Ebrahimi Warkiani M
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551871
[TBL] [Abstract][Full Text] [Related]
14. Methylation pattern of caveolin-1 in prostate cancer as potential cfDNA biomarker.
Škara L; Vodopić T; Pezelj I; Abramovic I; Vrhovec B; Vrtarić A; Sincic N; Tomas D; Bulimbašić S; Kuliš T; Ulamec M
Biomol Biomed; 2023 Feb; 23(1):176-186. PubMed ID: 36036057
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumour DNA - looking beyond the blood.
Tivey A; Church M; Rothwell D; Dive C; Cook N
Nat Rev Clin Oncol; 2022 Sep; 19(9):600-612. PubMed ID: 35915225
[TBL] [Abstract][Full Text] [Related]
16. The utility of cfDNA in TGCT patient management: a systematic review.
Krasic J; Skara L; Bojanac AK; Ulamec M; Jezek D; Kulis T; Sincic N
Ther Adv Med Oncol; 2022; 14():17588359221090365. PubMed ID: 35656387
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial Power of cfDNA, CTCs and EVs in Oncology.
Keup C; Kimmig R; Kasimir-Bauer S
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453918
[TBL] [Abstract][Full Text] [Related]
18. Transcending Blood-Opportunities for Alternate Liquid Biopsies in Oncology.
Werner B; Warton K; Ford CE
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267615
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
